Merck Recommends Rejection Of TRC Capital's "Mini-Tender" Offer To Purchase Up To 1M Shares Of Common Stock At $96.38 Per Share
Merck Recommends Rejection Of TRC Capital's "Mini-Tender" Offer To Purchase Up To 1M Shares Of Common Stock At $96.38 Per Share
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated November 12, 2024, to purchase up to 1,000,000 shares of Merck common stock at $96.38 per share. The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024 ($100.73), the last trading day before the date of the offer, and approximately 3.48% below the closing price of the Merck common stock on November 21, 2024 ($99.86), the day prior to this release.
默沙东（纽交所：MRK），在美国和加拿大以外被称为MSD，已收到通知，TRC资本投资公司（TRC Capital）于2024年11月12日发起了一项未经请求的"迷你收购"要约，拟以每股96.38美元购买最多1,000,000股默沙东普通股。该要约价格大约低于2024年11月11日默沙东普通股的收盘价4.32%（100.73美元），这是该要约发布前的最后交易日，并且大约低于2024年11月21日默沙东普通股的收盘价3.48%（99.86美元），这是本公告发布前一天。
Merck does not endorse TRC Capital's offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital's unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck's shares (as of the day prior to this release) and is subject to numerous conditions, including TRC Capital's ability to obtain financing. Merck is not associated in any way with TRC Capital, its mini-tender offer or the offer documentation.
默沙东不支持TRC资本的要约，并建议默沙东股东拒绝该要约，不要根据TRC资本的未经请求的迷你收购要约进行股份投标。该迷你收购要约的价格低于默沙东股份的收盘价（截至本公告前一天），并受多项条件的限制，包括TRC资本获得融资的能力。默沙东与TRC资本、其迷你收购要约或要约文件没有任何关联。
